Eur Rev Med Pharmacol Sci 2003; 7 (5): 139-145

Safety of conventional drugs and biologic agents for Rheumatoid Arthritis

A. Amoroso, A. Gigante, C. Gianni, D. Amoroso, D. Zennaro*, S. Galluzzo, D. Caccavo**

Dpt. of Clinical Medicine, University of Rome “La Sapienza” – Rome (Italy)
* Dpt. of Internal Medicine, Campus Bio-Medico University – Rome (Italy)
** Dpt. of Clinical Medicine, Immunology and Infectious Diseases, University of Bari (Italy)

Abstract. – While initial researches documented that Rheumatoid Arthritis (RA) patients who took biologic agents had decreased symptoms with those receiving traditional treatment, safety of the drugs remains a concern. The Authors in this paper review the safety of the RA new therapeutic approach utilizing biological agents and compare it with the safety of conventional disease-modifying anti-rheumatic drugs (DMARDs).

Free PDF Download

To cite this article

A. Amoroso, A. Gigante, C. Gianni, D. Amoroso, D. Zennaro*, S. Galluzzo, D. Caccavo**
Safety of conventional drugs and biologic agents for Rheumatoid Arthritis

Eur Rev Med Pharmacol Sci
Year: 2003
Vol. 7 - N. 5
Pages: 139-145

Keywords Related articles:

  1. Prescribing patterns and clinical outcomes of biological disease-modifying anti-rheumatic drugs for rheumatoid arthritis in Spain
  2. A review of network meta-analysis comparing biologics in the treatment of rheumatoid arthritis
  3. New biological agents for the treatment of the “high risk” IBD patients
  4. May Etanercept and PTH (1-34) association heal erosions in early rheumatoid arthritis? A pilot study
  5. MiR-20a regulates fibroblast-like synoviocyte proliferation and apoptosis in rheumatoid arthritis